Hospital
Boulder Community Health
Boulder Community Health was paid $7.84M by Medicaid between Jan 2018 and Dec 2024, across 86 billing codes. Its largest line is 99283, emergency room visit (moderate) — 39% of everything it billed.
33Billing provider infoBOULDER COMMUNITY HEALTH
BOULDER, CO 80303
BOULDER, CO 80303
33aNPI1821074196assigned 12/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.84M
24GClaims142,435
24DCodes billed86
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#17 of 51
Median peer was paid$1.24M
This provider vs. median6.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,186 | $975K | |
| 2019 | 18,057 | $956K | |
| 2020 | 13,208 | $538K | |
| 2021 | 23,182 | $1.25M | |
| 2022 | 35,017 | $1.75M | |
| 2023 | 22,505 | $1.37M | |
| 2024incomplete | 12,280 | $1.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 39% | 26,423 | 21,358 | $3.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 16,321 | 13,376 | $1.68M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 10,493 | 8,200 | $1.12M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.4% | 3,239 | 2,492 | $737K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 9,522 | 7,856 | $178K |
| 0002A | 2.0% | 1,849 | 1,706 | $157K | |
| 0001A | 1.7% | 1,758 | 1,550 | $135K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 525 | 364 | $84K |
| 80053 | Comprehensive metabolic panel | <1% | 4,556 | 3,469 | $70K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,717 | 1,602 | $68K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 298 | 245 | $53K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 472 | 443 | $46K |
74 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 473 | $45K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,434 | $43K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,735 | $35K |
| 87536 | <1% | 456 | $31K | |
| 0004A | <1% | 436 | $31K | |
| 80320 | <1% | 211 | $19K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,184 | $16K |
| 0071A | <1% | 213 | $14K | |
| 0064A | <1% | 184 | $14K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,441 | $14K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,687 | $14K |
| 80047 | <1% | 3,884 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 177 | $11K |
| 0031A | <1% | 125 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,653 | $10K |
| 0072A | <1% | 140 | $10K | |
| 80364 | <1% | 86 | $8K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 150 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 31 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 286 | $7K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 252 | $6K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 33 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 135 | $5K |
| 0012A | <1% | 59 | $5K | |
| 80076 | <1% | 365 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 286 | $5K |
| 84484 | <1% | 805 | $5K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 215 | $5K |
| 86703 | <1% | 113 | $4K | |
| 0054A | <1% | 127 | $4K | |
| 86780 | <1% | 96 | $4K | |
| 0011A | <1% | 43 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,754 | $4K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 110 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 65 | $3K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 77 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 88 | $3K |
| 97602 | <1% | 44 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 732 | $2K |
| 0003A | <1% | 18 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 25 | $1K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 51 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 142 | $1K |
| 86360 | <1% | 31 | $1K | |
| 86803 | <1% | 38 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 22 | $1K |
| 86359 | <1% | 43 | $973.54 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,177 | $966.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $507.43 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $365.60 |
| 84703 | <1% | 793 | $193.55 | |
| 84439 | <1% | 14 | $183.68 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 138 | $152.52 |
| 83690 | <1% | 934 | $136.84 | |
| 85014 | <1% | 2,185 | $108.06 | |
| 81001 | <1% | 112 | $95.01 | |
| 82248 | <1% | 1,285 | $75.38 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 549 | $4.80 |
| 85610 | <1% | 91 | $3.97 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,201 | $2.14 |
| 99253 | 0% | 12 | $0.00 | |
| 85730 | 0% | 74 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 48 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 15 | $0.00 |
| 83735 | 0% | 35 | $0.00 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 110 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 28 | $0.00 |
| 85027 | 0% | 64 | $0.00 | |
| 71046 | Radiologic examination, chest; 2 views | 0% | 212 | $0.00 |
| 80305 | 0% | 101 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 264 | $0.00 |
| 81003 | 0% | 13 | $0.00 | |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 12 | $0.00 |
| 80306 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUNSON, WILLIAM (VICE PRESIDENT / CFO)
| Provider | Location | Paid |
|---|---|---|
| Boulder Community Health | Boulder, CO | $2.73M |
| Boulder Community Health Sports Medicine Imaging LLC | Boulder, CO | $879.65 |
| Boulder Community Health | Boulder, CO | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.